Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention

https://doi.org/10.20996/1819-6446-2019-15-6-918-927

Full Text:

Abstract

Recently, there has been a positive trend to reduce mortality from myocardial infarction. One of the reasons for such dynamics is the development of angiographic service in our country and the increase in the number of primary percutaneous coronary interventions. One of the most serious complications of endovascular interventions affecting the prognosis is the development of the phenomenon of slow or unrecoverable blood flow (≪slow/no-reflow≫ phenomenon). The reason for the development of this phenomenon is associated, first of all, with distal embolization by thrombotic masses and fragments of atherosclerotic plaque. In order to prevent this complication, manual thromboextraction was developed – the aspiration of thrombotic masses from the infarct-related artery. The manual thrombus aspiration has not been proven effective in a number of large randomized trials. In addition to the lack of influence on the prognosis, the method of manual thrombus aspiration significantly more often led to the development of ischemic strokes and currently should not be routinely carried out. Another method of preventing the phenomenon of delayed or unrecoverable blood flow is the use of glycoprotein IIb/IIIa receptor inhibitors which is, in contrast to the instrumental method, effective and relatively safe. According to a number of large randomized trials, drug treatment of this complication influences life expectancy in patients with ST-elevation myocardial infarction. At a time when there is already a meta-analysis on the routine use of glycoprotein IIb/IIIa receptor inhibitors during primary percutaneous coronary intervention and their positive impact on survival, in our country, unfortunately, the importance of these drugs is underestimated and according to the register they are used only in 3% of patients with ST-segment elevation myocardial infarction. This review presents studies and comparisons of glycoprotein IIb/IIIa receptor inhibitors existing on the market.

About the Authors

A. S. Tereshchenko
National Medical Research Centre of Cardiology
Russian Federation

Andrey S. Tereshchenko – MD, PhD, Researcher, Department of Endovascular Methods of Diagnosis and Treatment

Tretya Cherepkovskaya ul. 15A, Moscow, 121552



Е. V. Merkulov
National Medical Research Centre of Cardiology
Russian Federation

Evgeny V. Merkulov – MD, PhD, Senior Researcher, Department of Endovascular Methods of Diagnosis and Treatment

Tretya Cherepkovskaya ul. 15A, Moscow, 121552



A. M. Samko
National Medical Research Centre of Cardiology
Russian Federation

Anatoly N. Samko – MD, PhD, Professor, Head of the Department of Endovascular Methods of Diagnosis and Treatment

Tretya Cherepkovskaya ul. 15A, Moscow, 121552



References

1. Chazov E.I., et al. Cardiology Guide. Diseases of the cardiovascular system. Vol. 3. Moscow: Praktika; 2014 (In Russ)

2. Oshchepkova E.V., Efremova I.E., Karpov I.A. Morbidity and mortality from myocardial infarction in the Russian Federation in 2000-2011.Terapevticheskii Arkhiv. 2013;(4):4-10 (In Russ.)

3. Mortality by cause of death in 2018. Federal State Statistics Service [cited by Dec 04, 2019]. Available from: https://www.gks.ru/storage/mediabank/demo24-2.xls (In Russ.)

4. Alekian B.G., Grigorian А.M., Staferov A.V., Karapetian N.G. Endovascular diagnosis and treatment in the Russian Federation (2018). Endovaskuliarnaia Khirurgiia. 2019;(6):2 (In Russ.)

5. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;(39):119-177. DOI:10.1093/eurheartj/ehx792.

6. Тereshchenko A.S., Merkulov E.V., Shakhnovich R.M., Samko A.N. Manual thromboextraction in patients with acute myocardial infarction with ST segment elevation. Atherothrombosis. 2016;(1):3950 (In Russ.) DOI:10.21518/2307-1109-2016-1-39-49.

7. Antman E.A., Cohen M., Bernink P.J., et al. The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI. JAMA. 2000;(284):835-42. DOI:10.1001/jama.284.7.835.

8. Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101(2):125-30. DOI:10.1161/01.cir.101.2.125.

9. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;(29):2909-45. DOI:10.1016/s0195-668x(02)00618-8.

10. Vlaar P.J., Svilaas T., van der Horst I.C., et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;(371):1915-20. DOI:10.1016/s01406736(08)60833-8.

11. Francesco B., De Vita M., Gu Y.L., et al. Clinical impact of thrombectomy in acute ST elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;(30):2193-203. DOI:10.1093/eurheartj/ehp348.

12. El-Jack S.S., Suwatchai P., Stewart J.T., et al. Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. J Interv Cardiol. 2007;(20):474-80. DOI:10.1111/j.1540-8183.2007.00308.x.

13. Frobert O., Lagerqvist B., Olivecrona G.K., et al. Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. N Engl J Med. 2013;(369):1587-97. DOI:10.1056/nejmoa1308789.

14. Jolly S.S., Cairns J., Yusuf S., et al. Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. Am Heart J. 2014;(167):315-21. DOI:10.1016/j.ahj.2013.12.002.

15. De Jong M.J., Wright S.L. New adjunctive therapy for ischemic syndromes. Crit Care Nurs Clin North Am. 1999;11(3):355-71. DOI:10.1016/s0899-5885(18)30152-7.

16. Pevzner D.V., Gertsenberg M.Z., Mazurov A.V., Vlasik T.N. On the use of the antiplatelet agent ruciromab for the prevention of thrombosis in coronary angioplasty in patients with coronary heart disease. Kardiologiia. 2015;55(12):125-32 (In Russ.) DOI:10.18565/cardio.2015.12.90-98.

17. Makhiianova E.I., Galiavich A.S. The efficacy and safety of the monofram IIb/IIIa glycoprotein receptor blocker in coronary stenting of patients with acute myocardial infarction. Rational Pharmacotherapy in Cardiology. 2011;7(4):452-6 (In Russ.). DOI:10.20996/1819-6446-2011-7-4-452-456.

18. Yalcin V., Tolga S.G., Koray D., et al. Effects of Bailout Tirofiban on In-Hospital Outcomes and LongTerm Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. Angiology. 2019;70(5):431-9. DOI:10.1177/0003319718808911.

19. Ten Berg J.M., Van't Hof A.W., Dill T., et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on shortand long-term clinical outcome. J Am Coll Cardiol. 2010;55(22):2446-55. DOI:10.1016/j.jacc.2009.11.091

20. Van't Hof A.W., Ten Berg J., Heestermans T., et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial. Lancet. 2008;(372):537-46. DOI:10.1016/s01406736(08)61235-0.

21. Zhang Z., Li W., Wu W., et al. Myocardial reperfusion with tirofiban injection via aspiration catheter: Efficacy and safety in STEMI patients with large thrombus burden. Herz. 2018;(12). DOI:10.1007/s00059-018-4716-0.

22. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;(8):734-41. DOI:10.1161/01.cir.98.8.734.

23. Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;(35):915-21. DOI:10.1016/s07351097(99)00635-x.

24. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;(334):1895-903. DOI:10.1056/NEJM200106213442503.

25. Mahmoudi M., Delhaye C., Wakabayashi K., et al. Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Interv Cardiol. 2011;24(4):351-6. DOI:10.1111/j.1540-8183.2011.00632.x.

26. Zeymer U., Zahn R., Schiele R., et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005;(26):1971-7. DOI:10.1093/eurheartj/ehi293.

27. Gibson M., Kirtane A.J., Murphy S.A., et al. TIMI Study Group Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)TIMI 34 trial. Am Heart J. 2006;(152):668-75. DOI:10.1016/j.ahj.2006.06.003.

28. Akerblom A., James S.K., Koutouzis M., et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol. 2010;56(6):470-5. DOI:10.1016/j.jacc.2009.10.093.

29. Gurm H.S., Smith D.E., Collins J.S., et al. The Relative Safety and Efficacy of Abciximab and Eptifibatide in Patients Undergoing Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2007;51(5):529-35. DOI:10.1016/j.jacc.2007.09.053.

30. Protocol COR-INT / 2012. Clinline Clinical Trials Search Platform [cited by Dec 04, 2019]. Available from: https://clinline.ru/reestr-klinicheskih-issledovanij/646-14.10.2013.html (In Russ.)

31. Acute myocardial infarction with elevation of the ST segment of the electrocardiogram. Clinical recommendations [cited by Dec 04, 2019]. Available from: http://cr.rosminzdrav.ru/#!/schema/135 (In Russ.)

32. Belle L., Cayla G., Cottin Y., et al. French Registry on Acute ST-elevation and non−ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data. Arch Cardiovasc Dis. 2017;110(6-7):366-78. DOI:10.1016/j.acvd.2017.05.001.

33. Brahmajee K., Sharon-Lise T., Yongfei W., et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. Lancet. 2015;(385):1114-22. DOI:10.1016/s0140-6736(14)61932-2.

34. Erlikh A.D., GratsianskiĭN.A. on behalf of the REKORD-3 register participants. Russian registry of acute coronary syndrome «RECORD-3». Characterization of patients and treatment before discharge from the hospital. Kardiologiia. 2016;4(16):16-24 (In Russ.) DOI:10.1016/j.gheart.2016.03.162.

35. Karathanos A., Lin Y., Dannenberg L., et al. Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis. Can J Cardiol. 2019;35(11):1576-88. DOI:10.1016/j.cjca.2019.05.003.


For citation:


Tereshchenko A.S., Merkulov Е.V., Samko A.M. Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology. 2019;15(6):918-927. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-6-918-927

Views: 102


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)